Blue Water Biotech acquires six FDA-approved drugs for $8.5M cash and 1M shares

Onconetix, Inc.

Total consideration $8.5M cash (payable in three tranches) plus 1.0M restricted shares of BWV common stock.
Assets include ZONTIVITY (PAD/MI), OTOVEL/CETRAXAL (otic), CONJUPRI (hypertension), TREZIX/NALFON (pain).
Closing subject to delivery of audited 2022 financials of seller’s parent and other customary conditions.
Company will manage assets during pre-closing period; Blue Water becomes commercial-stage biopharma.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Onconetix, Inc. entered into Purchase Agreement with WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC (effective 2023-06-13).

Action: entry
Agreement: asset purchase
Counterparty: WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC
Effective: 2023-06-13

Exact text from the filing

On June 13, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with WraSer, LLC, a Mississippi limited liability company, Xspire Pharma, LLC, a Mississippi limited liability company (collectively, the “Seller”), and Legacy-Xspire Holdings, LLC, a Delaware limited liability company and the parent company of the Seller (“Parent”).

View on SEC.gov

246 material agreements filed in the last 30 days. Browse all material agreements →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-048740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.